<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00635713</url>
  </required_header>
  <id_info>
    <org_study_id>9238IL/0021</org_study_id>
    <secondary_id>D6995C00021</secondary_id>
    <nct_id>NCT00635713</nct_id>
  </id_info>
  <brief_title>Second Line Breast Cancer Trial</brief_title>
  <official_title>A Double-Blind, Randomized, Multi-Center Trial Comparing the Efficacy and Tolerability of 125 and 250mg of Faslodex (Long Acting ICI 182,780) With 1mg Arimidex (Anastrazole) in Postmenopausal Women With Advanced Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The main purpose of this study is to compare the effect of 2 doses of FASLODEX with 1 dose of
      ARIMIDEX in terms of time to tumor progression in postmenopausal women with advanced breast
      cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 1997</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to tumor progression</measure>
    <time_frame>Every 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective tumor response</measure>
    <time_frame>Every 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to treatment failure</measure>
    <time_frame>Every 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to death</measure>
    <time_frame>Every 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">588</enrollment>
  <condition>Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Faslodex 125mg and Arimidex 1 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Faslodex 250mg and Arimidex 1mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>125mg</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Faslodex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>ARIMIDEX</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>250mg</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Faslodex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  postmenopausal women with confirmation of breast cancer

          -  objective evidence of recurrence or progression of breast cancer no more than 1 prior
             hormonal therapy for breast cancer

        Exclusion Criteria:

          -  presence of life-threatening metastatic visceral disease

          -  previous treatment with FASLODEX, ARIMIDEX or any aromatase inhibitor for breast
             cancer

          -  more than 1 prior endocrine medical treatment for advanced breast cancer .
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guido Hoctin-Boes</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2008</study_first_submitted>
  <study_first_submitted_qc>March 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2008</study_first_posted>
  <last_update_submitted>April 9, 2009</last_update_submitted>
  <last_update_submitted_qc>April 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2009</last_update_posted>
  <keyword>Advanced breast cancer, FASLODEX, ARIMIDEX, Fulvestrant, Anastrozole, postmenopausal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

